MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Metrics, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Metrics, Inc. Expands with Fast-track Pharmaceutical Product Development Laboratory - Along with Gerteis Mini-Pactor®, capital investments reflect ongoing commitment to contract services - MetricsInc.com
Metrics, Inc. Expands with Fast-track Pharmaceutical Product Development Laboratory

 

NewswireToday - /newswire/ - Greenville, NC, United States, 2014/02/18 - Along with Gerteis Mini-Pactor®, capital investments reflect ongoing commitment to contract services - MetricsInc.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Metrics Inc. is making significant investments in its facilities and equipment for the benefit of contract services clients by opening a new laboratory to better support fast-track development of pharmaceutical products.

Also in its Greenville facility, the company is adding to its equipment portfolio a Gerteis Mini-Pactor, a high pressure-precise roller compactor that provides Metrics’ formulation development scientists even greater flexibility in batch sizes and throughput.

The fast-track development laboratory and Gerteis Mini-Pactor represent continuing investment efforts at Metrics to support the changing needs of its contract services clients, said Stefan Cross, president of Mayne Pharma USA, the parent company of Metrics.

About the fast-track development laboratory

The $1.6 million, 4,524-square-foot facility located on the company’s main campus in Greenville, N.C. provides maximum flexibility for early formulation and analytical method development.

The facility is designed for pre-clinical development of early formulation prototypes and related analytical methods. In this laboratory setting, formulators and chemists will have significant autonomy to conduct development activities more quickly, explained Dr. Brad Gold, vice president of pharmaceutical development.

Segregated from the main Metrics operations and containing fully dedicated equipment, these new processing suites have independent HVAC systems and state-of-the-art engineering controls such as interlocking airlock doors, room air pressure differentials, high-volume room air turnover, and 100-percent HEPA air filtration.

“These suites offer our scientists tremendous flexibility, which will support the fast-track development of drug products,” Gold said. “Prototype formulations and methods developed in this lab will be transferred to the adjacent facility for further development and manufacture of clinical trial materials and registration batches. There, they will be manufactured under the exacting auspices of current Good Manufacturing Practice so that Metrics will continue to deliver proven scientific and operational excellence in oral solid dosage forms.”

The ground floor of the new facility consists of five processing rooms and one analytical laboratory. The second floor consists of workstations, office space and a conference room. This project increases to 16 the total number of processing rooms, which are in addition to the extensive analytical laboratories and large-scale manufacturing and packaging operations that Metrics has available. The new facility is expected to be fully operational by mid-February, Gold said.

About the Gerteis Mini-Pactor

Housed within Metrics’ main facility, the company’s new Gerteis Mini-Pactor has capacity ranging from 10 grams for pilot projects to 100 kilograms per hour for small-scale production, making it especially useful in a formulation development laboratory setting, Gold said.

“While big pharma companies may already be familiar with this particular roller compactor, Metrics can be considered an early adopter among pharmaceutical contract development and manufacturing organizations,” he said. “This equipment investment reflects Metrics’ ongoing commitment to operational excellence and to conducting science that is most meaningful to our clients and the patients we collectively serve.”

About Metrics

Metrics Inc. (metricsinc.com) is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. Our company’s areas of expertise include quality pharmaceutical formulation development; first-time-in-man (FTIM) formulations; clinical trial materials (CTM) manufacturing for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.

Metrics’ capabilities include highly potent, cytotoxic and unstable compounds, Schedule II-V controlled substances, and products with poor bioequivalence for which we offer an impressive portfolio of advanced delivery methods.

Metrics proudly operates as a subsidiary of Mayne Pharma Group Limited. Learn more about the new fast-track development laboratory at our website.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Metrics, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Metrics, Inc. Expands with Fast-track Pharmaceutical Product Development Laboratory

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Karen Stinneford - Sinclair-Co.com for Metrics 
919-833-9102 kys[.]sinclair-co.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Metrics, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Metrics, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)